Cipla receives USFDA nod for nasal spray for treating migraine attacks
Drug major Cipla on Tuesday said
it has received final approval from the United States Food and Drug
Administration (USFDA) for Sumatriptan Nasal Spray, indicated for the treatment
of migraine attacks.
The newly approved product is a generic therapeutic equivalent
version of GlaxoSmithKline's Imitrex Nasal Spray.
The company has received final approval for its abbreviated new
drug application (ANDA) for Sumatriptan Nasal Spray, 20 mg from the United
States Food and Drug Administration (USFDA), Cipla said in a
regulatory filing.
Quoting IQVIA (IMS Health) data, Cipla said Imitrex
Nasal Spray 20mg and its generic equivalents had US sales of approximately USD
53.3 million for the 12-month period ending December 2020.
Shares of Cipla were trading 0.88 per cent higher at Rs 796.45
apiece on BSE.
Comments
Post a Comment